Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

About us

Our Mission

To develop novel cancer medicines inspired by RNA biology. Our team of experienced drug developers is focused on generating innovative medicines that address difficult to treat cancers​.

041118_JBascom_2T0A5934-1024x683
Inspirna is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target critical cancer drivers.

Using a novel discovery platform, RNA-DRIVEr™, developed by Inspirna’s founding scientists at Rockefeller University, and now exclusively licensed to Inspirna, we are developing first-in-class small molecule and biologic therapeutics that target cancer drivers in high unmet need oncology settings.​

Rgenix-lab-new-york

Inspirna’s Approach to Oncology Drug Development